Regulation of melanocortin 1 receptor expression at the mRNA and protein levels by its natural agonist and antagonist

被引:38
|
作者
Rouzaud, F [1 ]
Annereau, JP [1 ]
Valencia, JC [1 ]
Costin, GE [1 ]
Hearing, VJ [1 ]
机构
[1] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA
来源
FASEB JOURNAL | 2003年 / 17卷 / 12期
关键词
promoter; 5 ' untranslated region (5 ' UTR); melanocyte; translation;
D O I
10.1096/fj.03-0206fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Five melanocortin receptors, which form a subfamily of G protein-coupled receptors, are expressed in mammalian tissues and regulate such diverse physiological processes as pigmentation, adrenal function, energy homeostasis, feeding efficiency, and sebaceous gland lipid production, as well as immune and sexual function. Pigmentation in mammals is stimulated by alpha-melanocyte stimulating hormone (MSH), which binds to the melanocortin 1 receptor (Mclr) and induces an activation of melanogenic enzymes through stimulation of adenylate cyclase and protein kinase A. The antagonist agouti signal protein (ASP) interacts with the Mclr and blocks its stimulation by MSH. We examined the influence of ASP or MSH on Mclr gene expression, and we report that both ligands influence the Mclr 5' promoter structure in distinct manners. Our study further shows that MSH regulates Mclr function at both the mRNA and protein levels, whereas ASP acts only on its translation.
引用
收藏
页码:2154 / +
页数:21
相关论文
共 50 条
  • [1] Isolation and characterization of antagonist and agonist peptides to the human melanocortin 1 receptor
    Bonetto, S
    Carlavan, I
    Baty, D
    PEPTIDES, 2005, 26 (11) : 2302 - 2313
  • [2] Agouti-related protein: Conversion from a Melanocortin receptor antagonist to agonist
    Haskell-Luevano, Carrie
    Edison, Arthur S.
    Wilczynski, Andrzej
    Wilson, Krista R.
    Joseph, Christine G.
    Xiang, Zhimin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [3] Gene Expression Regulation by Agonist-Independent Constitutive Signaling of Melanocortin-1 Receptor
    Seong, Ikjoo
    Kim, Jaesang
    ENDOCRINOLOGY AND METABOLISM, 2014, 29 (02) : 179 - 184
  • [4] Antagonist and agonist activities of the mouse Agouti protein fragment (91-131) at the melanocortin-1 receptor
    Eberle, AN
    Bódi, J
    Orosz, G
    Süli-Vargha, H
    Jäggin, V
    Zumsteg, U
    JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 2001, 21 (01): : 25 - 45
  • [5] Common requirements for melanocortin-4 receptor selectivity of structurally unrelated melanocortin agonist and endogenous antagonist, Agouti protein
    Oosterom, J
    Garner, KM
    den Dekker, WK
    Nijenhuiss, WAJ
    Gispen, WH
    Burbach, JPH
    Barsh, GS
    Adan, RAH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (02) : 931 - 936
  • [6] Melanocortin Antagonist Tetrapeptides with Minimal Agonist Activity at the Mouse Melanocortin-3 Receptor
    Doering, Skye R.
    Todorovic, Aleksandar
    Haskell-Luevano, Carrie
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (02): : 123 - 127
  • [7] Regulation of TNF-α secretion by a specific melanocortin-1 receptor peptide agonist
    Ignar, DM
    Andrews, JL
    Jansen, M
    Eilert, MM
    Pink, HM
    Lin, PY
    Sherrill, RG
    Szewczyk, JR
    Conway, JG
    PEPTIDES, 2003, 24 (05) : 709 - 716
  • [8] Dynamic regulation of hypothalamic neuropeptide gene expression and food intake by melanocortin analogues and reversal with melanocortin-4 receptor antagonist
    Kim, RY
    Shin, SW
    Kim, BJ
    Lee, W
    Baik, JH
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (04) : 1178 - 1185
  • [9] Increased selectivity and potency of melanocortin receptor agonist and antagonist by using [γ]-MSH analogues
    Cai, M
    Stankova, M
    Cabello, C
    Balse, P
    Mayorov, A
    Trivedi, D
    Hruby, VJ
    BIOPOLYMERS, 2003, 71 (03) : 377 - 377
  • [10] Regulation of 5-HT2A receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin
    Anji, A
    Kumari, M
    Hanley, NRS
    Bryan, GL
    Hensler, JG
    NEUROPHARMACOLOGY, 2000, 39 (11) : 1996 - 2005